Funding will Advance Lead Drug in Type 1 Diabetes and Develop HLA-Targeted Therapeutic Platform in Autoimmune Disorders AURORA, Colo. & BOSTON, October 9, 2019-- ImmunoMolecular Therapeutics (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, today announced that it has raised $10 million in Series A financing to advance its novel HLA-targeted discovery platform and develop its lead drug candidate in type 1 diabetes (T1D). The funding was co-led by the JDRF T1D Fund and Morningside Ventures, with participation from the Colorado University Healthcare Innovation Fund.